Liposomes formulated with fmlp-modified cholesterol for enhancing drug concentration at inflammatory sites

Journal of Drug Targeting

Volumn 22, Issue 2, 2014, Pages 165-174

  Qin, Yao ^a,b   Li, Zi Wei ^a,c   Yang, Yong ^a   Yu, Chun Mei ^d   Gu, Dan Dan ^a   Deng, Hong ^a   Zhang, Tao ^e   Wang, Xin ^a   Wang, Ai Ping ^a   Luo, Wei Zao ^a  

^a Chong qing Acad Chin Materia Med   (China)

^b Taiji Group   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d PKU International Healthcare Group Chongqing Daxin Pharmaceutical Co Ltd   (China)

^e Chongqing Pharmaceutical Research Institute Co Ltd   (China)

Author keywords

Cholesterol; Differentiated U937; FMLP; in vitro; in vivo; Liposome

Indexed keywords

ANTIINFLAMMATORY AGENT; CHOLESTEROL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LIPOSOME; MACROGOL; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; DRUG TARGETING; DRUG UPTAKE; EX VIVO STUDY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; INFLAMMATION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTI-INFLAMMATORY AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; LIPOSOMES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; U937 CELLS;

EID: 84891779553     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.851683     Document Type: Article

References (26)

1. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005;6:1191-7.
2. Garcia Rodriguez LA, Hernandez Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12: 570-6.
3. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454:445-54.
4. Villanueva FS, Jankowski RJ, Klibanov S, et al. Microbubbles targeted to intercellular adhension molecule-1 bind to activated coronary artery endothelial cells. Circulation 1998;98:1-5.
5. Klibanov AL, Hughes MS, Villanueva FS, et al. Targeting and ultrasound imaging of microbubble-based contrast agents. Magma 1999;8:177-84.
6. Demos SM, Alkan-Onyuksel H, Kane BJ, et al. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J Am Coll Cardiol 1999;33:867-75.
7. Prossnitz ER, Ye RD. The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol Therapeut 1997;74:73-102.
8. Le Y, Yang Y, Cui Y, et al. Receptors for chemotactic formyl peptides as pharmacological targets. Int Immunopharmacol 2002;2: 1-13.
9. Crielaard BJ, Lammers T, Morgan ME, et al. Macrophages and liposomes in inflammatory disease: friends or foes? Int J Pharm 2011;416:499-506.
10. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561-2.
11. Zhao XB, Muthusamy N, Byrd JC, Lee RJ. Cholesterol as a bilayer anchor for PEGylation and targeting ligands in folate-receptortargeted liposomes. J Pharm Sci 2007;96:2424-39.
12. Miller CR, Bondurant B, Mc Lean SD, et al. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998;37:12875-83.
13. Parr MJ, Ansell SM, Choi LS, Cullis PR. Factors influencing the retention and chemical stability of poly (ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta 1994;1195:21-30.
14. Qin Y, Fan W, Chen H, et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target 2010; 18:536-49.
15. Qin Y, Chen H, Zhang Q, et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 2011;420: 304-12.
16. Maeda N, Takeuchi Y, Takada M, et al. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 2004;100:41-52.
17. Han HD, Lee A, Song CK, et al. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm 2006;313:181-8.
18. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med 1982;155:264-75.
19. Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 2010;145: 178-81.
20. Minafra L, Di Cara G, Albanese NN, Cancemi P. Proteomic differentiation pattern in the U937 cell line. Leukemia Res 2011;35: 226-36.
21. Wan L, Zhang X, Pooyan S, et al. Optimizing size and copy number for PEG-fMLP (N-Formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages. Bioconjugate Chem 2008;19: 28-38.
22. Qin Y, Chen H, Yuan W, et al. Liposome formulated with TATmodified cholesterol for enhancing the brain delivery. Int J Pharm 2011;419:85-95.
23. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003;13:195-208.
24. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003;7:626-34.
25. Xu RX, Young DC, Mao JJ, Povoski SP. A prospective pilot clinical trial evaluating the utility of a dynamic near-infrared imaging device for characterizing suspicious breast lesions. Breast Cancer Res Tr 2007;9:R88.
26. Tromberg BJ, Pogue BW, Paulsen KD, et al. Assessing the future of diffuse optical imaging technologies for breast cancer management. Med Phys 2008;35:243-51.